Sudhir Sahasrabudhe
Direttore/Membro del Consiglio presso Utah State University Foundation
Profilo
Sudhir Sahasrabudhe is currently an Associate Member at Massachusetts Institute of Technology and a Trustee at Utah State University Foundation.
He previously worked as Acting CEO & Chief Scientific Officer at Prolexys Pharmaceuticals, Inc., Senior Director-Biotechnology at Aventis Pharmaceuticals, Inc., and Executive Vice President-Research & Development at Myriad Genetics, Inc. Dr. Sahasrabudhe received his undergraduate and graduate degrees from the University of Baroda and his doctorate in 1987 from the same institution.
Posizioni attive di Sudhir Sahasrabudhe
| Società | Posizione | Inizio |
|---|---|---|
| Utah State University Foundation | Direttore/Membro del Consiglio | - |
| Massachusetts Institute of Technology | Corporate Officer/Principal | - |
Precedenti posizioni note di Sudhir Sahasrabudhe
| Società | Posizione | Fine |
|---|---|---|
| MYRIAD GENETICS, INC. | Direttore Tecnico/Scientifico/R&S | - |
Aventis Pharmaceuticals, Inc.
 Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | Direttore Tecnico/Scientifico/R&S | - |
Prolexys Pharmaceuticals, Inc.
 Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Amministratore Delegato | - |
Formazione di Sudhir Sahasrabudhe
| University of Baroda | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| MYRIAD GENETICS, INC. | Health Technology |
| Aziende private | 3 |
|---|---|
Aventis Pharmaceuticals, Inc.
Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | Health Technology |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Health Technology |
| Utah State University Foundation |
- Borsa valori
- Insiders
- Sudhir Sahasrabudhe
